Abstract: Objective To investigate the effect of OCA2 nucleotide rs4778137 polymorphism on neoadjuvant chemotherapy for triple negative breast cancer.
Methods A total of 72 patients diagnosed with triple negative breast cancer and treated with neoadjuvant chemotherapy in our hospital from February 2016 to March 2020 were selected as study subjects.DNA kit was used to extract total DNA from peripheral blood.DNA chip was used to detect rs4778137 polymorphism,and the correlation between rs4778137 polymorphism of OCA2 and pathological complete response rate(pCR) after neoadjuvant chemotherapy was analyzed.Logistic regression analysis was used to analyze the independent risk factors on the pCR rate.
Results The TNBC patients with pCR rate,disease course of more than 2 years,at T3 and T4,and with lymphatic metastasis was lower.The frequencies of CC,GC and GG genotypes at rs4778137 were 20.8%,29.2% and 50.0%,respectively,and the pCR rate was 20.0%,28.6% and 52.8%,respectively(P<0.05).T stage,lymphatic metastasis and rs4778137 polymorphism were independent risk factors on pCR rate of TNBC patients(P<0.05).
Conclusion rs 4778137 polymorphism is related to  pCR rate of neoadjuvant chemotherapy in TNBC patients,and the pCR rate is higher in GG genotypes.

Key words: OCA2 rs4778137, triple negative breast cancer, neoadjuvant chemotherapy